Dogwood Therapeutics (DWTX) Accumulated Expenses (2020 - 2026)

Dogwood Therapeutics (DWTX) has reported Accumulated Expenses for 7 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 70.76% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (up 70.76% YoY), while the FY2025 annual figure was $2.2 million, up 436.82% from the prior year.
• Accumulated Expenses rose to $2.3 million in Q1 2026 per DWTX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $2.3 million in Q1 2026 and bottomed at $46799.0 in Q3 2023.
• Historically, Accumulated Expenses has averaged $560258.8 across 5 years, with a median of $236851.0 in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 94.91% — and 2025, when it surged 1363.65%.
• Dogwood Therapeutics' Accumulated Expenses stood at $159704.0 in 2022, then jumped by 54.43% to $246635.0 in 2023, then soared by 69.29% to $417539.0 in 2024, then jumped by 436.82% to $2.2 million in 2025, then advanced by 4.79% to $2.3 million in 2026.
• Business Quant data shows DWTX's Accumulated Expenses at $2.3 million in Q1 2026, $2.2 million in Q4 2025, and $188085.0 in Q3 2025.